News & Events about Agenus Inc.
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven ODay, Chief Medical Officer, will participate ...
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for standard of care and other investigational therapiesResponses have been durable with 69% ongoing at ...
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven ODay, Chief Medical Officer, will participate in a ...
LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in ...
Ticker Report
2 months ago
Agenus Inc. (NASDAQ:AGEN Get Rating) Research analysts at William Blair lowered their FY2023 earnings per share (EPS) estimates for Agenus in a research note issued to investors on Monday, November 14th. William Blair analyst M. Phipps now expects that the biotechnology company will ...